GlobeNewsWire·Jun 30, 2026
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton SyndromeASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd.(QNRX)Earnings, Financials & Key Ratios
QNRX•NASDAQ
$4.80
Price updated Jul 7, 2026
AboutQuoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.Show more
- Revenue$0
- EBITDA-$16M-71.7%
- Net Income-$16M-76.3%
- EPS (Diluted)-10.63+84.1%
- ROE-141.59%-17.4%
QNRX Price & Volume
Quoin Pharmaceuticals, Ltd. (QNRX) stock price & volume — 10-year historical chart
Loading chart...
Escalating Clinical Burn Rates Threaten Equity Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- Quoin Pharmaceuticals faces a precarious financial outlook characterized by a complete lack of revenue and an R&D burn rate that has surged to $3.4 million as of 2026Q1.
- The company's reliance on dilutive financing to sustain its clinical-stage pipeline is evidenced by a deep retained earnings deficit of $76.0 million.
- Investors should remain cautious as the firm's operational sustainability remains entirely dependent on external capital infusions to offset persistent quarterly net losses.
Verdict Logic
the company's $3.1 million cash position is insufficient to cover the current quarterly R&D burn rate of $3.4 million, signaling a high probability of further shareholder dilution.
QNRX Growth Metrics
Quoin Pharmaceuticals, Ltd. (QNRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-62.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.39%
Return on Capital
10 Years9.77%
5 Years-111.81%
3 Years-104.79%
Last Year-123.55%
QNRX Recent Earnings
Quoin Pharmaceuticals, Ltd. (QNRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.77+18.4%
$2.17
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$14.80-130.5%
$6.42
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$6.71-5.5%
$6.36
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$6.28+8.1%
$6.83
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.77vs $2.17+18.4% | — |
| Q2 2026 | Mar 26, 2026 | $14.80vs $6.42-130.5% | — |
| Q4 2025 | Nov 6, 2025 | $6.71vs $6.36-5.5% | — |
| Q3 2025 | Aug 7, 2025 | $6.28vs $6.83+8.1% | — |
Based on last 12 quarters of dataView full earnings history →
Latest QNRX News
Recent stock market news and headlines for Quoin Pharmaceuticals, Ltd. (QNRX)
GlobeNewsWire·Jun 23, 2026
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton SyndromeQRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027 Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16 QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
GlobeNewsWire·Jun 18, 2026
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
GlobeNewsWire·Jun 16, 2026
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use ProgramFour of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or ‘Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 Years of Age, with the Youngest Being Just 6 Months Old Duration of Treatment To-Date Ranges from 3 Weeks to 15 Months No Treatment Related Adverse Events Reported for All Six Patients Additional Pediatric Patients Enrolling in Program in June and September Quoin Plans a Comprehensive Data Release, including from Ongoing Phase 2 Studies, in the Coming Months ASHBURN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Peers Comparison
Key metrics vs top competitors for Quoin Pharmaceuticals, Ltd. (QNRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.80 | $9.41M | -0.45 | — | — | -141.59% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — |
Compare QNRX vs Peers
Quoin Pharmaceuticals, Ltd. (QNRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QNRX SEC Filings & Documents
Quoin Pharmaceuticals, Ltd. (QNRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Mar 11, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when QNRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QNRX Frequently Asked Questions
Quoin Pharmaceuticals, Ltd. (QNRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is QNRX profitable?
Quoin Pharmaceuticals, Ltd. (QNRX) reported a net loss of $17.0M for fiscal year 2025.
Dividend & Returns
What is QNRX's return on equity?
Quoin Pharmaceuticals, Ltd. (QNRX) has a return on equity (ROE) of -141.6%. Negative ROE indicates the company is unprofitable.
What is Quoin Pharmaceuticals, Ltd.'s free cash flow?
Quoin Pharmaceuticals, Ltd. (QNRX) had negative free cash flow of $15.9M in fiscal year 2025, likely due to heavy capital investments.